nach oben

Erschienen in:

01.09.2012 | Original Article

Comparison of circadian characteristics for cytotoxic lymphocyte subsets in non-small cell lung cancer patients versus controls

verfasst von: Gianluigi Mazzoccoli, Robert B. Sothern, Paola Parrella, Lucia A. Muscarella, Vito Michele Fazio, Francesco Giuliani, Victoria Polyakova, Igor M. Kvetnoy

Erschienen in: Clinical and Experimental Medicine | Ausgabe 3/2012

Einloggen, um Zugang zu erhalten

Abstract

Lymphocyte subsets are major cellular components of the adaptive immune response and in most cases show 24-h (circadian) variations in health. In order to determine overall levels and circadian characteristics of cytotoxic natural killer (NK) and T and B lymphocyte subsets, blood samples were collected every 4 h for 24 h from eleven male controls (C) without neoplastic disease and nine men with untreated non-small cell lung cancer (NSCLC) and analyzed for 3 hormones (melatonin, cortisol, and interleukin 2 [IL2]) and for 11 lymphocyte subpopulations classified by cell surface clusters of differentiation (CD) and antigen receptors. Circadian rhythmicity for each variable was evaluated by ANOVA and 24 h cosine fitting and groups compared. Rhythms in melatonin and cortisol (peaks near 01:30 and 08:00 h) indicated identical synchronization to the light–dark schedule and probable persistent entrainment of rhythms for both groups in metabolism or proliferation of healthy tissues normally tightly coupled to the sleep–wake cycle. Twenty-four hours means were significantly higher in NSCLC for CD16, CD25, cortisol, and IL2 and lower for CD8, CD8bright, and γδTCR. A significant circadian rhythm was found in C with daytime peaks for CD8, CD8dim, CD16, Vδ2TCR, and cortisol and nighttime peaks for CD3, CD4, CD20, and melatonin, and in NSCLC, with daytime peaks for CD16, γδTCR, Vδ2TCR and cortisol, and nighttime peaks for CD4, CD25, and melatonin. Thus, NSCLC was associated with significant increases or decreases in proportions for several lymphocyte subsets that may reflect disease development, but peak times were nevertheless similar between C and NSCLC for each variable, suggesting that timed circadian administration (chronotherapy) of immunotherapy and other cancer treatments may improve efficacy due to persistent circadian entrainment of healthy tissues.

de Visser KE, Eichten A, Coussens LM (2006) Paradoxical roles of the immune system during cancer development. Nat Rev Cancer 6(1):24–37PubMedCrossRef

Zhang T, Herlyn D (2009) Combination of active specific immunotherapy or adoptive antibody or lymphocyte immunotherapy with chemotherapy in the treatment of cancer. Cancer Immunol Immunother 58(4):475–492PubMedCrossRef

Blank C, Mackensen A (2007) Contribution of the PD-L1/PD-1 pathway to T-cell exhaustion: an update on implications for chronic infections and tumor evasion. Cancer Immunol Immunother 56(5):739–745PubMedCrossRef

Zang X, Allison JP (2007) The B7 family and cancer therapy: costimulation and coinhibition. Cancer Res 13(18 Pt 1):5271–5279

Inman BA, Frigola X, Dong H, Kwon ED (2007) Costimulation, coinhibition and cancer. Curr Cancer Drug Targets 7(1):15–30 ReviewPubMedCrossRef

June CH, Blazar BR, Riley JL (2009) Engineering lymphocyte subsets: tools, trials and tribulations. Nat Rev Immunol 9(10):704–716PubMedCrossRef

Motohashi S, Nakayama T (2008) Clinical applications of natural killer T cell-based immunotherapy for cancer. Cancer Sci 99(4):638–645PubMedCrossRef

Zhang YL, Li J, Mo HY et al (2010) Different subsets of tumor infiltrating lymphocytes correlate with NPC progression in different ways. Mol Cancer 10(9):4CrossRef

Savas B, Kerr PE, Pross HF (2006) Lymphokine-activated killer cell susceptibility and adhesion molecule expression of multidrug resistant breast carcinoma. Cancer Cell Int 6:24–37PubMedCrossRef

10.

Kabelitz D, Wesch D, He W (2007) Perspectives of gammadelta T cells in tumor immunology. Cancer Res 67(1):5–8PubMedCrossRef

11.

Mantovani A, Bottazzi B, Colotta F, Sozzani S, Ruco L (1992) The origin and function of tumor-associated macrophages. Immunol Today 13(7):265–270PubMedCrossRef

12.

Allavena P, Sica A, Solinas G, Porta C, Mantovani A (2008) The inflammatory micro-environment in tumor progression: the role of tumor-associated macrophages. Oncol Hematol 66(1):1–9

13.

van Ravenswaay Claasen HH, Kluin PM, Fleuren GJ (1992) Tumor infiltrating cells in human cancer. On the possible role of CD16+ macrophages in antitumor cytotoxicity. Lab Invest 67(2):166–174PubMed

14.

Sothern RB (2006) Clinical medicine. In: Koukkari WL, Sothern RB (eds) Introducing biological rhythms. Springer, New York, pp 426–525

15.

Haus E (2007) Chronobiology in the endocrine system. Adv Drug Deliv Rev 59(9–10):985–1014PubMedCrossRef

16.

Edery I (2000) Circadian rhythms in a nutshell. Physiol Genomics 3(2):59–74PubMed

17.

Hastings MH, Reddy AB, Maywood ES (2003) A clockwork web: circadian timing in brain and periphery, in health and disease. Nat Rev Neurosci 4:649–661PubMedCrossRef

18.

Gachon F, Nagoshi E, Brown SA, Ripperger J, Schibler U (2004) The mammalian circadian timing system: from gene expression to physiology. Chromosoma 113:103–112PubMedCrossRef

19.

Ko CH, Takahashi JS (2006) Molecular components of the mammalian circadian clock. Hum Mol Genet 15:R271–R277 ReviewPubMedCrossRef

20.

Damiola F, Le Minh N, Preitner N, Kornmann B, Fleury-Olela F, Schibler U (2000) Restricted feeding uncouples circadian oscillators in peripheral tissues from the central pacemaker in the suprachiasmatic nucleus. Genes Dev 14:2950–2961PubMedCrossRef

21.

Stokkan KA, Yamazaki S, Tei H, Sakaki Y, Menaker M (2001) Entrainment of the circadian clock in the liver by feeding. Science 291:490–493PubMedCrossRef

22.

Fu L, Lee CC (2004) The circadian clock: pacemaker and tumour suppressor. Nature Rev Cancer 3:350–361CrossRef

23.

Nagoshi E, Saini C, Bauer C, Laroche T, Naef F, Schibler U (2004) Circadian gene expression in individual fibroblasts: cell-autonomous and self-sustained oscillators pass time to daughter cells. Cell 119:693–705PubMedCrossRef

24.

Mazzoccoli G, Correra M, Bianco G et al (1997) Age-related changes of neuro-endocrine-immune interactions in healthy humans. J Biol Reg Hom Agents 11(4):143–147

25.

Suzuki S, Toyabe S, Moroda T (1997) Circadian rhythm of leucocytes and lymphocytes subsets and its possible correlation with the function of the autonomic nervous system. Clin Exp Immunol 110(3):500–508PubMedCrossRef

26.

Mazzoccoli G, Sothern RB, De Cata A et al (2011) A timetable of 24-hour patterns for human lymphocyte subpopulations. J Biol Regul Homeost Agents (in press)

27.

Blum KS, Pabst R (2007) Lymphocyte numbers and subsets in the human blood. Do they mirror the situation in all organs? Immunol Lett 108(1):45–51PubMedCrossRef

28.

Dimitrov S, Benedict C, Heutling D, Westermann J, Born J, Lange T (2009) Cortisol and epinephrine control opposing circadian rhythms in T cell subsets. Blood 113(21):5134–5143PubMedCrossRef

29.

Dimitrov S, Lange T, Born J (2010) Selective mobilization of cytotoxic leukocytes by epinephrine. J Immunol 184(1):503–511PubMedCrossRef

30.

Mazzoccoli G, De Cata A, Greco A, Carughi S, Giuliani F, Tarquini R (2010) Circadian rhythmicity of lymphocyte subpopulations and relationship with neuro-endocrine system. J Biol Reg Homest Agents 24(3):341–350

31.

Teboul M, Barrat-Petit M-A, Mei Li X, Claustrat B, Formento J-L, Delaunay F (2005) Atypical patterns of circadian clock gene expression in human peripheral blood mononuclear cells. J Mol Med 83(9):693–699PubMedCrossRef

32.

Fukuya H, Emoto N, Nonaka H, Yagita K, Okamura H, Yokoyama M (2007) Circadian expression of clock genes in human peripheral leukocytes. Biochem Biophys Res Commun 354(4):924–928PubMedCrossRef

33.

Borgs L, Beukelaers P, Vandenbosch R, Belachew S, Nguyen L, Malgrange B (2009) Cell “circadian” cycle: new role for mammalian core clock genes. Cell Cycle 8(6):832–837PubMedCrossRef

34.

Estrela-Lima A, Araújo MS, Costa-Neto JM et al (2010) Immunophenotypic features of tumor infiltrating lymphocytes from mammary carcinomas in female dogs associated with prognostic factors and survival rates. BMC Cancer 10:256PubMedCrossRef

35.

Mazzoccoli G, Grilli M, Carughi S et al (2003) Immune system alterations in lung cancer patients. Int J Immunopathol Pharmacol 16(2):167–174PubMed

36.

Sharma P (2009) Preanalytical variables and laboratory performance. Ind J Clin Biochem 24:109–110CrossRef

37.

Göhde W, Cassens U, Lehman LG et al (2003) Individual patient-dependent influence of erythrocyte lysing procedures on flow-cytometric analysis of leukocyte subpopulations. Transfus Med Hemother 30:165–170CrossRef

38.

Klerman EB, Gershengorn HB, Duffy JF, Kronauer RE (2002) Comparisons of the variability of three markers of the human circadian pacemaker. J Biol Rhythms 17(2):181–193PubMedCrossRef

39.

Nelson W, Tong YL, Lee YK, Halberg F (1979) Methods for cosinor rhythmometry. Chronobiologia 6(4):305–323PubMed

40.

Mojón A, Fernández JR, Hermida R (1992) Chronolab: an interactive software package for chronobiologic time series analysis written for the Macintosh computer. Chronobiol Intl 9(6):403–412CrossRef

41.

Parmiani G (2005) Tumor-infiltrating T cells—friend or foe of neoplastic cells? N Engl J Med 353(25):2640–2641PubMedCrossRef

42.

Bindea G, Mlecnik B, Fridman WH, Pagès F, Galon J (2010) Natural immunity to cancer in humans. Curr Opin Immunol 22(2):215–222PubMedCrossRef

43.

Mantovani A (2010) Molecular pathways linking inflammation and cancer. Curr Mol Med 10(4):369–373 ReviewPubMedCrossRef

44.

O’Callaghan DS, O’Donnell D, O’Connell F, O’Byrne KJ (2010) The role of inflammation in the pathogenesis of non-small cell lung cancer. J Thorac Oncol 5(12):2024–2036 ReviewPubMedCrossRef

45.

Allavena P, Germano G, Marchesi F, Mantovani A (2011) Chemokines in cancer related inflammation. Exp Cell Res 317(5):664–673 ReviewPubMedCrossRef

46.

Thompson RH, Dong H, Kwon ED (2007) Implications of B7-H1 expression in clear cell carcinoma of the kidney for prognostication and therapy. Clin Cancer Res 13(2 Pt 2):709s–715sPubMedCrossRef

47.

Ghebeh H, Barhoush E, Tulbah A, Elkum N, Al-Tweigeri T, Dermime S (2008) FOXP3+ Tregs and B7-H1+/PD-1+ T lymphocytes co-infiltrate the tumor tissues of high-risk breast cancer patients: implication for immunotherapy. BMC Cancer 23(8):57CrossRef

48.

Mazzoccoli G, Vendemiale G, De Cata A, Carughi S, Tarquini R (2010) Altered time structure of neuro-endocrine-immune system function in lung cancer patients. BMC Cancer 10(1):314PubMedCrossRef

49.

Hueman MT, Stojadinovic A, Storrer CE et al (2007) Analysis of naïve and memory CD4 and CD8 T cell populations in breast cancer patients receiving a HER2/neu peptide (E75) and GM-CSF vaccine. Cancer Immunol Immunother 56(2):135–146PubMedCrossRef

50.

Eckschlager T, Radvanska J, Slaby K, Prusa R, Hochova I, Radvansky J (2009) Changes of blood count, lymphocyte subpopulations and immunoglobulin levels in nephroblastoma long term survivors. Neoplasma 56(1):9–12PubMedCrossRef

51.

Ormandy LA, Hillemann T, Wedemeyer H, Manns MP, Greten TF, Korangy F (2005) Increased populations of regulatory T cells in peripheral blood of patients with hepatocellular carcinoma. Cancer Res 65(6):2457–2464PubMedCrossRef

52.

Cesana GC, DeRaffele G, Cohen S et al (2006) Characterization of CD4+CD25+ regulatory T cells in patients treated with high-dose interleukin-2 for metastatic melanoma or renal cell carcinoma. J Clin Oncol 24(7):1169–1177PubMedCrossRef

53.

Beyer M, Kochanek M, Darabi K et al (2005) Reduced frequencies and suppressive function of CD4+CD25hi regulatory T cells in patients with chronic lymphocytic leukemia after therapy with fludarabine. Blood 106(6):2018–2025PubMedCrossRef

54.

Woo EY, Chu CS, Goletz TJ et al (2001) Regulatory CD4(+)CD25(+) T cells in tumors from patients with early-stage non-small cell lung cancer and late-stage ovarian cancer. Cancer Res 61(12):4766–4772PubMed

55.

Meloni F, Morosini M, Solari N et al (2006) Foxp3 expressing CD4+CD25+ and CD8+CD28− T regulatory cells in the peripheral blood of patients with lung cancer and pleural mesothelioma. Hum Immunol 67(1–2):1–12PubMedCrossRef

56.

Nelson BH (2008) The impact of T-cell immunity on ovarian cancer outcomes. Immunol Rev 222:101–116 ReviewPubMedCrossRef

57.

Ebelt K, Babaryka G, Frankenberger B et al (2009) Prostate cancer lesions are surrounded by FOXP3+, PD-1+ and B7-H1+ lymphocyte clusters. Eur J Cancer 45(9):1664–1672PubMedCrossRef

58.

Salama P, Phillips M, Grieu F et al (2009) Tumor-infiltrating FOXP3+ T regulatory cells show strong prognostic significance in colorectal cancer. J Clin Oncol 27(2):186–192PubMedCrossRef

59.

Karagöz B, Bilgi O, Gümüs M et al (2010) CD8+CD28− cells and CD4+CD25+ regulatory T cells in the peripheral blood of advanced stage lung cancer patients. Med Oncol 27(1):29–33PubMedCrossRef

60.

Chaput N, Louafi S, Bardier A et al (2009) Identification of CD8+CD25+Foxp3+ suppressive T cells in colorectal cancer tissue. Gut 58(4):520–529PubMedCrossRef

61.

Shen LS, Wang J, Shen DF et al (2009) CD4(+)CD25(+)CD127(low/-) regulatory T cells express Foxp3 and suppress effector T cell proliferation and contribute to gastric cancers progression. Clin Immunol 131(1):109–118PubMedCrossRef

62.

Cassone VM, Natesan AK (1997) Time and time again: the phylogeny of melatonin as a transducer of biological time. J Biol Rhythms 12:489–497 ReviewPubMedCrossRef

63.

Reiter RJ (1991) Pineal melatonin: cell biology of its synthesis and its physiological interactions. Endocr Rev 12:151–179PubMedCrossRef

64.

Reiter RJ, Tan DX, Fuentes-Broto L (2010) Melatonin: a multitasking molecule. Prog Brain Res 181:127–151 ReviewPubMedCrossRef

65.

Van Cauter E (1990) Diurnal and ultradian rhythms in human endocrine function: a minireview. Horm Res 34:45–53PubMedCrossRef

66.

Gusenoff JA, Harman S, Veldhuis JD et al (2001) Cortisol and GH secretory dynamics, and their interrelationships, in healthy aged women and men. Am J Physiol Endocrinol Metab 280:E616–E625PubMed

67.

Haus E (2007) Chronobiology in the endocrine system. Adv Drug Deliv Rev 59:985–1014PubMedCrossRef

68.

Lévi F, Okyar A, Dulong S, Innominato PF, Clairambault J (2010) Circadian timing in cancer treatments. Annu Rev Pharmacol Toxicol 50:377–421 ReviewPubMedCrossRef

69.

Ohdo S (2010) Chronotherapeutic strategy: rhythm monitoring, manipulation and disruption. Adv Drug Deliv Rev 62(9–10):859–875 ReviewPubMedCrossRef

70.

Mazzoccoli G, Giuliani F, Sothern RB (2011) Whole body circadian phase evaluated from melatonin and cortisol sampled every 4 h over 24 h in healthy men. Cancer Epidemiol (in press)

Titel: Comparison of circadian characteristics for cytotoxic lymphocyte subsets in non-small cell lung cancer patients versus controls
verfasst von: Gianluigi Mazzoccoli
Robert B. Sothern
Paola Parrella
Lucia A. Muscarella
Vito Michele Fazio
Francesco Giuliani
Victoria Polyakova
Igor M. Kvetnoy
Publikationsdatum: 01.09.2012
Verlag: Springer Milan
Erschienen in: Clinical and Experimental Medicine / Ausgabe 3/2012
Print ISSN: 1591-8890
Elektronische ISSN: 1591-9528
DOI: https://doi.org/10.1007/s10238-011-0153-6

Leitlinien kompakt für die Innere Medizin

Mit medbee Pocketcards sicher entscheiden.

^{Seit 2022 gehört die medbee GmbH zum Springer Medizin Verlag}

Kostenlos registrieren

Update Innere Medizin

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

Newsletter bestellen

Live-Webinar "Urologie und Sexualmedizin in der Praxis"

Springer Medizin

Comparison of circadian characteristics for cytotoxic lymphocyte subsets in non-small cell lung cancer patients versus controls

Abstract

Leitlinien kompakt für die Innere Medizin

Neu im Fachgebiet Innere Medizin

Costims – das nächste heiße Ding in der Krebstherapie?

Perioperative Checkpointhemmer-Therapie verbessert NSCLC-Prognose

Positiver FIT: Die Ursache liegt nicht immer im Dickdarm

GLP-1-Agonisten können Fortschreiten diabetischer Retinopathie begünstigen

Update Innere Medizin

Live-Webinar "Urologie und Sexualmedizin in der Praxis"

Springer Medizin

Abstract

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 3/2012

A phase I pilot trial of MUC1-peptide-pulsed dendritic cells in the treatment of advanced pancreatic cancer

Up-regulated biglycan expression correlates with the malignancy in human colorectal cancers

Malignant tumor-like gastric lesion due to candida albicans in a diabetic patient treated with cyclosporin: a case report and review of the literature

VP22 enhances the expression of glucocerebrosidase in human Gaucher II fibroblast cells mediated by lentiviral vectors

High-dose thiotepa, etoposide and carboplatin as conditioning regimen for autologous stem cell transplantation in patients with high-risk non-Hodgkin lymphoma

Altered IL-10 and TNF-α production in peripheral blood mononuclear cells of systemic lupus erythematosus patients after Toll-like receptor 2, 4, or 9 activation

Leitlinien kompakt für die Innere Medizin

Neu im Fachgebiet Innere Medizin

Costims – das nächste heiße Ding in der Krebstherapie?

Perioperative Checkpointhemmer-Therapie verbessert NSCLC-Prognose

Positiver FIT: Die Ursache liegt nicht immer im Dickdarm

GLP-1-Agonisten können Fortschreiten diabetischer Retinopathie begünstigen

Update Innere Medizin